BSE in-principle approval for rights issue; board to take up Letter of Offer on November 04, 2026
Evonile Pharma (formerly Novartis India) has received BSE's in-principle approval, dated October 30, 2026, for its proposed rights issue of partly paid up equity shares, for an aggregate amount not exceeding ₹9,000.00 million.
By ScoutQuest · · 2 min read
- Rights Issue Size (Aggregate)
- not exceeding ₹9,000.00 million
- BSE In-Principle Approval Date
- October 30, 2026
- Board Meeting Date (Letter of Offer)
- November 04, 2026
Rights issue moves a step forward
The company, Evonile Pharma Limited (formerly Novartis India Limited), has received the in-principle approval of BSE Limited on October 30, 2026 for its proposed rights issue. This follows the Board's earlier approval, intimated on October 08, 2026, for issuing partly paid up equity shares to eligible equity shareholders for an aggregate amount not exceeding ₹9,000.00 million (Rupees Nine Thousand Million only).
What is a rights issue
- A company offers new shares to its existing shareholders, usually in proportion to what they already hold.
- Here the shares are partly paid up, which means the amount is paid in instalments rather than all at once.
- Eligible shareholders normally get a chance to subscribe; the price, ratio and record date decide on what terms.
What happens on November 04, 2026
- The Board of Directors is scheduled to meet to consider and approve the Letter of Offer in connection with the rights issue.
- The Rights Issue Committee is proposed to meet to consider, decide and discuss matters in connection with the rights issue, including the issue price, entitlement ratio, record date and fractional entitlement, among others.
Why the Letter of Offer matters
The Letter of Offer is the formal document that sets out the terms on which shareholders are invited to subscribe. Together with the committee's decisions on price, ratio and record date, it turns the approval in principle into an offer that shareholders can act on.
What shareholders may watch for
- The issue price and whether the shares are partly paid, and the instalment schedule that follows from it.
- The entitlement ratio, which decides how many rights shares a holder is entitled to for the shares already held.
- The record date, which decides who is eligible to receive the offer.
- The treatment of fractional entitlement, since holdings that do not divide neatly into the ratio can produce fractions.
A rights issue increases the number of shares in issue when subscribed, so existing holdings can be diluted if a shareholder does not participate. The final size, price and ratio are to be decided at the November 04, 2026 meetings.
Also from Evonile Pharma
Evonile Pharma reports first results after change of control
3 Nov 2026
Evonile Pharma Q2 and H1 FY27 results update: Q2 revenue down 38% YoY after business-model change
3 Nov 2026
Board approves unaudited results for September 2026 quarter; auditors' limited review unmodified
3 Nov 2026
More numbers
- Rights issue aggregate amount (not exceeding)₹9,000.00 million
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.